iCeutica

What iCeutica does

iCeutica is a privately held pharmaceutical technology and product development company founded in 2003, headquartered in Princeton, New Jersey, with secondary operations in Philadelphia and Perth, Australia. The company's core asset is its proprietary SoluMatrix Fine Particle Technology, a dry milling process that produces submicron-sized drug particles 10 to 200 times smaller than conventional drug particles while preventing particle agglomeration. This technology improves drug dissolution and absorption, enabling lower effective doses (often 20-50% of standard doses), faster onset of action, reduced side effects, elimination or reduction of food effects, and creation of new intellectual property protection for reformulated drugs. The platform has been validated through three FDA-approved NSAID products (ZORVOLEX/diclofenac, TIVORBEX/indomethacin, and VIVLODEX/meloxicam) and supports a pipeline of 15+ candidates spanning pain and inflammation, oncology, and respiratory disease.

iCeutica operates a hybrid business model combining technology licensing and proprietary product development. Revenue is generated primarily through royalty streams from FDA-approved products commercialized by partners, supplemented by upfront payments, milestones, and collaboration fees from licensing deals. The company typically partners after Phase 1 or Phase 2 completion, with pharmaceutical partners responsible for later-stage development, manufacturing, and commercialization. Named licensees include Iroko Pharmaceuticals (which has commercialized the three approved NSAID products in the US and select global markets) and Churchill Pharmaceuticals (which developed an improved formulation of a prostate cancer product using SoluMatrix). The company also advances internal pipeline candidates independently and pursues both global and territory-based licensing arrangements. Customer relationships are enterprise-pharmaceutical in nature, targeting firms seeking to improve marketed or development-stage drugs through the 505(b)(2) regulatory pathway.

The company is backed by Phoenix IP Ventures, a private equity and venture capital fund specializing in life sciences, whose Senior Managing Partner Osagie Imasogie serves as Chairman of iCeutica's Board. Public disclosures indicate approximately $5 million in disclosed funding across four rounds between 2005 and 2011, with the last public material milestone (a key USPTO patent, No. 8,808,751) dated September 2014. Revenue figures are not publicly disclosed. The firm maintains 11-50 employees and pursues licensing opportunities through major industry conferences including BioPharma America, Bio Investor Forum, BioEurope, and AAPS.

Name

iCeutica

Legal name

iCeutica Inc.

Website

http://www.iceutica.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

iCeutica is a private Philadelphia/Princeton-based pharmaceutical technology company that licenses its proprietary SoluMatrix Fine Particle Technology to pharma partners for reformulating drugs into submicron particles, with three FDA-approved NSAID products commercialized by partner Iroko Pharmaceuticals and a pipeline in pain, oncology, and respiratory indications.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Development

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Crystallization, Particle Engineering & Micronization Services (HLAGAHAJ)

Keywords

• Pharmaceutical drug development
• Submicron particle technology
• Bioavailability enhancement
• Drug formulation services
• Pharmaceutical technology licensing

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing Royalties: iCeutica receives royalty revenue from sales of FDA-approved products developed using their SoluMatrix technology by partners (e.g., ZORVOLEX diclofenac capsules). Royalty payments from partner product sales form a key revenue stream.
2. Licensing and Collaboration Deals: Company seeks collaboration and out-licensing partners for development products at Phase 1 or Phase 2 completion. Partners contribute to later-stage development and commercialization. Global and territory-based licensing deals provide upfront and milestone payments.
3. Proprietary Product Development: iCeutica advances its own pipeline of product candidates in pain and inflammation, oncology, and respiratory diseases, creating potential for direct commercialization revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

iCeutica develops and licenses its proprietary SoluMatrix Fine Particle Technology, a dry milling process that produces submicron-sized drug particles 10 to 200 times smaller than conventional particles. The company reformulates approved and development-stage pharmaceuticals to improve bioavailability, reduce or eliminate food effects, and enable efficacy at lower doses. It also advances an internal pipeline of product candidates in pain and inflammation, oncology, and respiratory diseases, and licenses its technology to pharmaceutical partners for commercialization.

Product overview

iCeutica operates as a pharmaceutical product development company with a dual business model: (1) providing services to pharmaceutical partners using its proprietary SoluMatrix™ Fine Particle Technology platform, and (2) developing proprietary product candidates in-house. The core SoluMatrix™ technology creates submicron drug particles 10-200 times smaller than conventional particles, improving bioavailability and enabling lower doses. Three FDA-approved products have resulted from partnerships: Zorvolex™ (diclofenac), Tivorbex™ (indomethacin), and Vivlodex® (meloxicam) — all NSAIDs commercialized with Iroko Pharmaceuticals. The company also advances internal pipeline candidates including ICE 1201 (metaxalone reformulation) for pain, oncology products (including prostate cancer), and inhaled respiratory products for asthma/COPD.

Differentiator

Problem solved

Functional benefit

Brands

• SoluMatrix™ Fine Particle Technology: Proprietary technology platform that creates submicron-sized drug particles 10-200 times smaller than conventional drug particles, improving drug dissolution and absorption.
• Zorvolex™ (diclofenac)
• Tivorbex™ (indomethacin)
• Vivlodex® (meloxicam)
• ICE 1201

Products and services

• SoluMatrix Fine Particle Technology Proprietary dry milling technology that reduces drug particles to submicron sizes (10-200 times smaller than conventional particles), improving dissolution, absorption, and enabling lower doses with potentially fewer side effects. Licensed to pharmaceutical partners for reformulating approved and development-stage drugs.
• Zorvolex (diclofenac) capsules FDA-approved NSAID utilizing SoluMatrix Fine Particle Technology, indicated for mild to moderate acute pain and osteoarthritis pain management, available at lower submicron doses than conventional diclofenac formulations.
• Tivorbex (indomethacin) capsules FDA-approved NSAID at 20mg and 40mg doses utilizing SoluMatrix Fine Particle Technology, indicated for mild to moderate acute pain in adults.
• Vivlodex (meloxicam) capsules FDA-approved NSAID utilizing SoluMatrix Fine Particle Technology, indicated for pain management with potentially lower doses and reduced side effects compared to conventional meloxicam formulations.
• ICE 1201 (Metaxalone SoluMatrix) Clinical-stage submicron reformulation of the metaxalone muscle relaxant designed to provide faster onset, lower doses, reduced variability, and fewer side effects compared to Skelaxin.
• Respiratory Product Candidates Inhaled product candidates addressing asthma, COPD, and allergic disease, characterized by consistent content uniformity, aerodynamic properties, and nano-structured increased surface area provided by SoluMatrix technology.
• Oncology Product Candidates Orally-administered cancer drug formulations utilizing SoluMatrix technology to overcome solubility issues, potentially enabling reduced doses and fewer side effects. Includes a prostate cancer program developed with Churchill Pharmaceuticals.
• Formulation Development Services Performance-enhancement services for pharmaceutical partners including formulation development, analytical analysis, method development, prototyping, and manufacturing capabilities, integrated as a cost-effective and reliable development partner offering.

Quantifiable outcome

• Drug particles 10-200 times smaller than conventional particles
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Iroko PharmaceuticalscoreOEM/ Whitelabel/ Licensing PartnerIroko Pharmaceuticals exclusively licensed iCeutica's SoluMatrix NSAID product candidates, designed to substantially reduce doses while preserving efficacy. Iroko progressed products through clinical trials and received FDA approval for three products: ZORVOLEX (diclofenac), TIVORBEX (indomethacin), and VIVLODEX (meloxicam). Products launched in USA and some global markets. iCeutica receives royalty revenue from product sales.
• Churchill PharmaceuticalscoreOEM/ Whitelabel/ Licensing PartnerChurchill Pharmaceuticals licensed SoluMatrix technology to develop a new and improved formulation of a well-known prostate cancer product. The original product is poorly dissolved in the body with high variability, resulting in inconsistent dosing. Churchill developed the new oncology product through late-stage patient trials with successfully improved product profile.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Xspray Pharma: Sweden-based pharmaceutical company that uses proprietary particle/amorphous engineering to create improved versions of approved drugs (initially PPIs). Closest comparable platform-level peer to iCeutica — both pursue 505(b)(2)-style reformulation of existing molecules via particle engineering with submicron/nano-scale processing.
• Nanoform Finland: Finnish nanoparticle drug formulation company using proprietary submicron/nanoparticle technology to improve bioavailability and dissolution of small-molecule APIs. Direct competitor to iCeutica's SoluMatrix in the particle-engineering pharmaceutical platform space.
• Ascendia Pharmaceuticals: New Jersey-based specialty CDMO focused on nano-formulation, microemulsion, and pre-formulation services for poorly soluble drugs. Direct competitor offering formulation platforms with similar bioavailability-enhancement positioning to SoluMatrix.
• Particle Sciences (Lubrizol Life Sciences): Specialty CDMO (now part of Lubrizol Life Sciences) focused on particulate drug delivery, including nano- and microparticle formulations for complex APIs. Direct formulation-services peer with substantial overlap in particle-engineering contract services.

Emerging players

• TFF Pharmaceuticals: Clinical-stage pharma company using thin-film freezing (TFF) technology to generate submicron/nanoparticle drug formulations with improved bioavailability. Smaller, narrower peer pursuing the same underlying problem (poorly soluble drugs) via a different particle-engineering technique.
• Dispersol Technologies: Early-stage drug delivery company developing proprietary particle engineering platforms (e.g., KinetiSol) for amorphous solid dispersions to enhance bioavailability. Niche emerging peer in the same pharmaceutical particle-engineering competitive space as SoluMatrix.

Broad incumbents

• Adare Pharmaceuticals: Global CDMO offering formulation development, particle engineering, and bioavailability enhancement services across multiple technology platforms. Broader incumbent offering overlapping formulation capabilities including particle size reduction.
• Bend Research (Lonza): Pioneer in particle engineering for bioavailability (now part of Lonza's Small Molecules CDMO business). Established incumbent offering spray-dried dispersions, hot-melt extrusion, and other solubilization technologies that compete broadly with SoluMatrix.
• Hovione: Portuguese CDMO with deep particle engineering expertise including micronization, nanonization, and amorphous solid dispersion capabilities. Established incumbent offering competing bioavailability-enhancement services at commercial scale.
• Catalent: Large global CDMO with broad formulation and softgel capabilities including OptiMicro particle engineering for poorly soluble drugs. Significant broader incumbent offering overlapping bioavailability-enhancement services to pharma partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iCeutica